JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 07/15/14

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Acute Coronary Syndrome (2)	FDA Third Complete Response 2/14	
		Stent Thrombosis for Acute Coronary Syndrome (2)	FDA Second Complete Response 2/14	
		Chronic Heart Failure	Phase III	
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill patients	Phase III	
	INVOKANA® (canagliflozin)/VOKANAMET® (canagliflozin and metformin fixed dose)	Fixed Dose Combination with Metformin (IR) (2)	FDA Complete Response 12/13 - Submitted Response to FDA 2/14	Approved 4/14
		Fixed Dose Combination with Metformin (XR) (2)	Phase III	
	INVOKANA® (canagliflozin)	Diabetic nephropathy	Phase III	Phase III
Immunology	STELARA® (ustekinumab)	Crohn's Disease	Phase III	Phase III
	SIMPONI® ARIA™(golimumab)	Rheumatoid Arthritis (IV)	Approved 7/13	Application withdrawn 5/14
	sirukumab	Rheumatoid Arthritis	Phase III	Phase III
Infectious Diseases and Vaccines	PREZISTA® (darunavir) and cobicistat (GS-9350)	Fixed Dose Combination HIV tablet for treatment naïve patients and treatment experienced patients	Filed 3/14	Filed 10/13
	OLYSIO® (simeprevir)	Chronic hepatitis C virus (HCV) infection for treatment naïve patients (2)	Approved 11/13	Approved 5/14
		Chronic hepatitis C virus (HCV) infection for treatment experienced patients, relapsers, and non-responders (2)	Approved 11/13	Approved 5/14
Neuroscience	INVEGA® (paliperidone ER OROS)	Pediatric indication - adolescent schizophrenia	Approved 4/11	Approved 5/14
	INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate IM long acting injectable)	Schizophrenia - 3 month injectable (2)	Phase III	Phase III
	INVEGA® SUSTENNA® (paliperidone palmitate)	Schizoaffective (2)	Filed 5/14	
Oncology	daratumumab	Relapsed/refractory multiple myeloma	Phase lll	Phase lll
	IMBRUVICA® (ibrutinib)	Relapsed/refractory patients with Chronic Lymphocytic Leukemia (single agent) (randomized study PCYC-1112) (2)	Filed 4/14	Phase III
		Relapsed/refractory patients with Chronic Lymphocytic Leukemia (single agent) (single arm phase II study PCYC-1102) (2)	Approved 2/14	Filed 10/13
		Relapsed/refractory patients with Chronic Lymphocytic Leukemia (in combination with Bendamustine and Rituximab) (randomized study CLL-3001) (2)	Phase III	Phase III
		Treatment naïve patients with Chronic Lymphocytic Leukemia (single agent) (randomized study PCYC-1115) (2)	Phase III	Phase III
		Relapsed/refractory with Mantle Cell Lymphoma (single agent) (randomized study MCL-3001) (2)	Phase III	Phase III
		Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Mantle Cell Lymphoma (single agent) (single arm phase II study PCYC-1104) (2)	Approved 11/13	Filed 10/13
		Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III
	JNJ56021927/ARN-509	Prostate cancer non-metastatic castration-resistant	Phase III	Phase III
	SYLVANT® (siltuximab)	Multicentric Castleman's Disease	Approved 4/14	Approved 5/14
	VELCADE® (bortezomib)	Mantle Cell Lymphoma 1st line (2)		Filed 6/14
	YONDELIS® (trabectedin)	Soft Tissue Sarcoma (2)	Phase III	
		Relapsed Ovarian Cancer	Phase III	
	ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic		Phase III

*** This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.**

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; PREZISTA/cobicistat developed in collaboration with Gilead Sciences; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; YONDELIS developed in collaboration with PharmaMar S.A.; XARELTO co-developed with Bayer HealthCare; INVEGA SUSTENNA developed in collaboration with Alkermes, Inc.; OLYSIO developed in collaboration with Medivir AB; Daratumumab licensed from Genmab A/S; IMBRUVICA devloped in collaboration with Pharmacyclics, Inc.; and Sirukumab developed in collaboration with GlaxoSmithKline.

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected Pharmaceutical Pipeline - Recent Approvals/Potential Filings*

Selective Highlights as of July 15, 2014

APPROVED 2013/2014

Cardiovascular & Metabolism

INVOKANA®
(canagliflozin)
Type 2 diabetes

Infectious Diseases & Vaccines

OLYSIO®
(simeprevir)
Chronic Hepatitis C virus

SIRTURO® (EU)
(bedaquiline)
Multi-drug resistant tuberculosis

Oncology

IMBRUVICA® (US)
(ibrutinib)
Previously treated Mantle Cell Lymphoma
Previously treated Chronic Lymphocytic Leukemia

SYLVANT®
(siltuximab)
Multicentric Castleman's disease

IN REGISTRATION

Oncology

Ibrutinib (EU)
Previously treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Previously treated Mantle Cell Lymphoma

PLANNED FILINGS 2014-2017*

Immunology

Sirukumab
Rheumatoid arthritis

Guselkumab
Psoriasis

Neuroscience

Esketamine
Treatment resistant depression

Oncology

Daratumumab
Relapsed/refractory multiple myeloma

YONDELIS® (US)
2nd Line soft tissue sarcoma

JNJ56021927 (ARN-509)
pre-metastatic prostate cancer

* Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. INVOKANA developed in collaboration with Mitsubishi Tanabe Pharma Corporation; OLYSIO developed in collaboration with Medivir AB; Sirukumab developed in collaboration with GlaxoSmithKline; IMBRUVICA developed in collaboration with Pharmacyclics, Inc.; Daratumumab licensed from Genmab A/S; YONDELIS developed in collaboration with Pharma Mar S.A.